Loading Episode...
The Bull & The Bear - Money & Markets EPISODE 55, 11th November 2020
Don’t Blindly Buy Into the Vaccine Hype — One Stock to Avoid
00:00:00 00:11:30

Don’t Blindly Buy Into the Vaccine Hype — One Stock to Avoid

The coronavirus has had the world in its grips for the better part of 2020.

For months, there seemed no end to the spread in sight. And new cases are still climbing higher as we enter the colder months.

But there’s good news!

This week, several companies announced either favorable results from vaccines or fast-track testing of potential vaccine candidates.

It provided a bright spot in what has otherwise been a year most of us would soon like to forget.

The news of a successful vaccine candidate was great news for investors.

In this episode of The Bull & The Bear, I’m going to look at one of companies that unveiled successful coronavirus vaccine results.

More importantly, I’ll tell you if the latest news makes the company one you should have in your portfolio.

I’ll run it through Chief Investment Strategist Adam O’Dell’s six-factor Green Zone Ratings system and tell you how the stock fares and what the numbers show us.

Be sure to also subscribe to our YouTube channel for more videos and information.

Have something you want us to talk about? Email us at thebullandthebear@moneyandmarkets.com and give us your thoughts.

Check out moneyandmarkets.com and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary and actionable advice.

Also, follow us on:

Facebook

Twitter

LinkedIn